Phase I evaluation shows limited efficacy of a monoclonal antibody in moderate-to-severe COVID-19 patients, indicating a need for adaptive strategies.
COR-101 demonstrated a favorable safety profile, but exploratory data showed limited efficacy against omicron, highlighting the tolerability of Fc-silenced mAbs and the need for adaptive therapeutic strategies against rapidly evolving viral pathogens (ClinicalTrials.gov identifier: NCT04674566).
No takes yet. Share an insight, caveat, or question.
Marconato et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: